College Financial Disclosure & COI Firewalls
The core purpose of the ACNP is to advance scientific understanding of and to facilitate communication about disorders of the brain and behavior in order to further their prevention and treatment. The ACNP has historically provided a venue at which the best scientists from academia, government, and industry have gathered to share, discuss, and debate their research. The meeting has served as a catalyst to advance discovery and disseminate information about scientific advances.
Like most professional medical societies, funding for the ACNP comes from a variety of sources including membership dues, royalties from publication sales, meeting registration fees, and grants from corporations or governmental agencies. The College has developed policies and procedures to either eliminate or to properly manage both real and perceived conflicts of interest and to separate financial issues from operational decisions. We have established firewalls to protect the integrity of College operations and to prevent the influence of financial sponsors from penetrating decision making processes of the College.
Click here to view these measures.
Click here to see a listing of all funds the College receives from drug companies.
Participating Corporations
Click here to learn more about the ACNP Participating Corporation Program.
The American College of Neuropsychopharmacology appreciates the support of our participating corporations:
Abbvie
ACADIA Pharmaceuticals Inc.
Alkermes, Inc.
Axsome Therapeutics, Inc.
Boehringer Ingelheim
CenExel Therapeutics
Cerevel Therapeutics, LLC
Clinilabs Drug Development Corporation
COMPASS Pathways
Delix Therapeutics
Eisai, Inc.
Engrail Therapeutics, Inc.
F. Hoffman-La Roche
H. Lundbeck A/S
Intra-Cellular Therapies, Inc.
IQVIA
Janssen Pharmaceuticals, Inc.
Karuna Therapeutics, Inc.
Merck & Co, Inc.
Neumora Therapeutics, Inc.
Neurocrine Biosciences, Inc.
Otsuka Pharmaceutical Development and Commercialization, Inc.
Sage Therapeutics, Inc.
Signant Health (Bracket Global)
Sunovion Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.
